The Centers for Medicare and Medicaid Services is likely to consent to pleas from patient groups and others to reverse a Trump Administration policy that would allow Medicare Part D plans participating in a payment demonstration project to cover only one drug in the protected classes beginning in 2022, essentially waiving the “substantially all” coverage requirement for the purposes of the experiment.
The change, made on the final day of the Trump Administration, was meant to attract more participation in the Medicare...








